A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
This study is being conducted to evaluate the safety and tolerability of INCA035784 in participants with myeloproliferative neoplasms.
Myeloproliferative Neoplasms
DRUG: INCA035784
Number of participants with Dose Limiting Toxicities (DLTs), Dose-limiting toxicity will be defined as the occurrence of any of the toxicities as per protocol., Up to 28 days|Number of participants with Treatment-emergent Adverse Events (TEAEs), Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug up to 90 days after the last dose of study drug., Up to approximately 2 years and 90 days|Number of participants with TEAEs leading to treatment interruption, discontinuation, or delay, Number of participants with TEAEs leading to treatment interruption, discontinuation, or delay., Up to approximately 2 years and 90 days
Number of participants with TEAEs leading to dose modification or discontinuation, Number of participants with TEAEs leading to dose modification or discontinuation., Up to approximately 2 years and 90 days|Participants with MF: Response using the revised International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) response criteria for myelofibrosis (MF), Defined as the percentage of participants with Response using the revised IWG-MRT and ELN response criteria., Up to approximately 2 years and 90 days|Participants with essential thrombocythemia (ET): Response using the revised IWG-MRT and ELN response criteria for ET, Defined as the percentage of participants with Response using the revised IWG-MRT and ELN response criteria., Up to approximately 2 years and 90 days|Participants with myelodysplastic syndrome (MDS)/MPN: Response using the revised IWG-MRT response criteria for MDS/MPN, Defined as the percentage of participants with Response using the revised IWG-MRT response criteria., Up to approximately 2 years and 90 days|Participants with symptomatic anemia: Anemia response, Anemia response as defined in the protocol., Up to approximately 2 years and 90 days|Participants with spleen volume (SV) ≥ 450 mL at baseline: Percentage of participants achieving spleen volume reduction of ≥ 35% (SVR35), Defined as percentage of participants with a protocol defined Spleen Volume Reduction of ≥ 35% (SVR35)., Week 12 and Week 24|Participants with SV ≥ 450 mL at baseline: Percentage of participants achieving spleen volume reduction of ≥ 25% (SVR25), Defined as percentage of participants with a protocol defined Spleen Volume Reduction of ≥ 25% (SVR25)., Week 12 and Week 24|Percentage of participants achieving ≥ 50% reduction from baseline of total symptom score (TSS), Defined as the percentage of participants achieving ≥ 50% reduction from baseline of TSS., Week 12 and Week 24|Mean change from baseline in TSS, Mean change of TSS from baseline., Week 12 and Week 24|Pharmacokinetics Parameter (PK): Cmax of INCA035784, Defined as maximum observed plasma concentration of INCA035784., Up to approximately 2 years and 90 days|Pharmacokinetics Parameter: Tmax of INCA035784, Defined as the time to reach the maximum plasma concentration of INCA035784., Up to approximately 2 years and 90 days|Pharmacokinetics Parameter: Cmin of INCA035784, Defined as the minimum observed plasma concentration of INCA035784., Up to approximately 2 years and 90 days|Pharmacokinetics Parameter: AUC(0-t) of INCA035784, Defined as the area under the concentration-time curve up to the last measurable concentration of INCA035784., Up to approximately 2 years and 90 days|Pharmacokinetics Parameter: AUC 0-∞ of INCA035784, Defined as the area under the concentration-time curve from 0 to infinity of INCA035784., Up to approximately 2 years and 90 days|Pharmacokinetics Parameter: CL of INCA035784, Defined as the apparent oral dose clearance of INCA035784., Up to approximately 2 years and 90 days|Pharmacokinetics Parameter: Vz of INCA035784, Defined as the apparent oral dose volume of distribution of INCA035784., Up to approximately 2 years and 90 days|Pharmacokinetics Parameter: t1/2 of INCA035784, Defined as the apparent terminal phase disposition half-life of INCA035784., Up to approximately 2 years and 90 days
This study is being conducted to evaluate the safety and tolerability of INCA035784 in participants with myeloproliferative neoplasms.